Masked Hypertension
Showing 1 - 25 of 8,019
Masked Hypertension With Smart Wearable Devices (SMART)
Not yet recruiting
- Masked Hypertension
- smart wearable device
-
Beijing, ChinaPeking University People's Hospital
Jun 3, 2022
Obstructive Sleep Apnea, Masked Hypertension Trial in Lleida (CPAP treatment)
Recruiting
- Obstructive Sleep Apnea
- Masked Hypertension
- CPAP treatment
-
Lleida, SpainHospital Universitari Arnau de Vilanova
May 4, 2022
Prevalence of Masked Hypertension in Nephrological Patients
Recruiting
- Masked Hypertension
- Comparison ABPM with OBPM
-
Zurich, SwitzerlandStadtspital Waid Zurich
Oct 27, 2021
Masked Hypertension Trial in Birmingham (Carvedilol, Amlodipine)
Withdrawn
- Masked Hypertension
-
Birmingham, AlabamaHypertension Research Clinic at UAB
Oct 28, 2021
Masked Hypertension Trial in Shanghai (Allisartan Isoproxil, Placebo)
Active, not recruiting
- Masked Hypertension
- Allisartan Isoproxil
- Placebo
-
Shanghai, Shanghai, ChinaRuijin Hospital
Sep 27, 2021
Masked Hypertension Trial in Milan, Maracaibo (Optimization of antihypertensive treatment based on office BP, Optimization of
Recruiting
- Masked Hypertension
- Optimization of antihypertensive treatment based on office BP
- Optimization of antihypertensive treatment based on 24-hour ABPM
-
Milan, Italy
- +1 more
Jan 25, 2022
Open Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (Travoprost Ophthalmic Topical Cream low-dose, Travoprost
Not yet recruiting
- Open Angle Glaucoma
- Ocular Hypertension
- Travoprost Ophthalmic Topical Cream low-dose
- +4 more
-
Newport Beach, CaliforniaGlaukos Clinical Study Site
Nov 22, 2023
Glaucoma Open-Angle Primary, Ocular Hypertension Trial in Albany (H-1337 0.6%, H-1337 1.0%, H-1337 Placebo)
Not yet recruiting
- Glaucoma Open-Angle Primary
- Ocular Hypertension
- H-1337 0.6%
- +3 more
-
Albany, GeorgiaDixon Eye Care
Jun 12, 2023
Wearable Blood Pressure Devices to Identify Masked Uncontrolled
Recruiting
- Hypertension,Essential
- Hypertension, Masked
-
Hsinchu, TaiwanNational Taiwan University Hospital Hsin-chu Branch
Apr 26, 2021
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye Trial
Not yet recruiting
- Primary Open Angle Glaucoma (POAG)
- +3 more
- Experimental: QLS-111 ophthalmic solution, (0.015%)
- +4 more
- (no location specified)
Aug 30, 2023
Glaucoma, Open-Angle, Hypertension, Ocular Trial in Austin (NCX 470, Latanoprost 0.005%)
Completed
- Glaucoma, Open-Angle
- Hypertension, Ocular
- NCX 470
- Latanoprost 0.005%
-
Austin, TexasTexan Eye
Nov 9, 2022
Cataract, Glaucoma, Ocular Hypertension Trial in Glendale (Bimatoprost Implant System (High Dose), Bimatoprost Implant System
Recruiting
- Cataract
- +2 more
- Bimatoprost Implant System (High Dose)
- +4 more
-
Glendale, ArizonaArizona Advanced Eye Research Institute
Nov 8, 2023
Ocular Hypertension Trial in Australia (FM101 tablet, FM101 oral solution, Placebo)
Recruiting
- Ocular Hypertension
- FM101 tablet
- +4 more
-
Bella Vista, New South Wales, Australia
- +4 more
Jul 18, 2022
Glaucoma, Open-Angle, Ocular Hypertension Trial in Winston-Salem (Brinzolamide/brimonidine ophthalmic suspension, Simbrinza
Completed
- Glaucoma, Open-Angle
- Ocular Hypertension
- Brinzolamide/brimonidine ophthalmic suspension
- Simbrinza 0.2%/1% Ophthalmic Suspension
-
Winston-Salem, North CarolinaJames D. Branch Ophthalmology
Aug 18, 2022
Primary Open Angle Glaucoma, Ocular Hypertension Trial in Glendale, Newport Beach, Cranberry Township (SBI-100 Ophthalmic
Recruiting
- Primary Open Angle Glaucoma
- Ocular Hypertension
- SBI-100 Ophthalmic Emulsion, 0.5%
- +2 more
-
Glendale, California
- +2 more
Nov 17, 2023
Glaucoma, Open-Angle Trial in Durham (VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic
Recruiting
- Glaucoma, Open-Angle
- VVN539 Ophthalmic Solution 0.02%
- +2 more
-
Durham, North CarolinaLexitas
Jul 19, 2022
Open Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (NCX 470 0.065%, NCX 470 0.1%, Latanoprost 0.005%)
Completed
- Open Angle Glaucoma
- Ocular Hypertension
- NCX 470 0.065% (initial phase of trial)
- +4 more
-
Newport Beach, CaliforniaEye Research Foundation
Oct 20, 2022
Glaucoma, Primary Open Angle, Ocular Hypertension Trial (TUG, Sham)
Terminated
- Glaucoma, Primary Open Angle
- Ocular Hypertension
- TUG
- Sham
- (no location specified)
Mar 28, 2022
Glaucoma, Open-Angle Trial in Colorado Springs (drug, other, device)
Recruiting
- Glaucoma, Open-Angle
- Travoprost Intraocular Implant
- +2 more
-
Colorado Springs, ColoradoGlaukos Clinical Study Site
Sep 27, 2023
Open-Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic
Completed
- Open-Angle Glaucoma
- Ocular Hypertension
- Nebivolol Ophthalmic Suspension 1 Percent
- +3 more
-
Newport Beach, CaliforniaSite 0012
Jul 18, 2022
Primary Open Angle Glaucoma, Ocular Hypertension Trial in Albany (QLS-101, Timolol Maleate)
Completed
- Primary Open Angle Glaucoma
- Ocular Hypertension
- QLS-101
- Timolol Maleate
-
Albany, GeorgiaDixon Eye Care
May 3, 2022
Open Angle Glaucoma, Ocular Hypertension Trial in Newport Beach (NCX 470 0.1%, Latanoprost 0.005%)
Recruiting
- Open Angle Glaucoma
- Ocular Hypertension
- NCX 470 0.1%
- Latanoprost 0.005%
-
Newport Beach, CaliforniaEye Research Foundation
Apr 26, 2022
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension Trial (Netarsudil 0.02% QD, Timolol maleate 0.5% BID)
Withdrawn
- OAG - Open-Angle Glaucoma
- OHT - Ocular Hypertension
- Netarsudil 0.02% QD
- Timolol maleate 0.5% BID
- (no location specified)
Mar 17, 2022
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital Trial in Durham (QLS-101ophthalmic solution 1%, QLS-101ophthalmic
Active, not recruiting
- Sturge-Weber Syndrome (SWS)
- +3 more
- QLS-101ophthalmic solution 1%
- QLS-101ophthalmic solution 2%
-
Durham, North CarolinaDuke Eye Center
Jul 19, 2022